Enasidenib (AG-221), A Selective Oral Inhibitor of Mutant Isocitrate Dehydrogenase 2 (IDH2) Enzyme, In Patients with Myelodysplastic Syndromes (MDS) von Stein, E.M, Fathi, A.T, DiNardo, C.D, Pollyea, D.A, Swords, R.T, Roboz, G.J, Collins, R, Sekeres, M.A, Stone, R.M, Attar, E.C, Tosolini, A, Xu, Q, Amatangelo, M, Gupta, I, Knight, R.D, de Botton, S, Tallman, M.S, Kantarjian, H.M

Volltext

1LBA Clinical safety and activity in a phase I trial of AG-120, a first in class, selective, potent inhibitor of the IDH1-mutant protein, in patients with IDH1 mutant positive adva... von Pollyea, D.A, de Botton, S, Fathi, A.T, Stein, E.M, Tallman, M.S, Agresta, S, Bowden, C, Fan, B, Prah, M, Yang, H, Yen, K, Stone, R.M

Volltext

38 - Enasidenib (AG-221), A Selective Oral Inhibitor of Mutant Isocitrate Dehydrogenase 2 (IDH2) Enzyme, In Patients with Myelodysplastic Syndromes (MDS) von Stein, E.M., Fathi, A.T., DiNardo, C.D., Pollyea, D.A., Swords, R.T., Roboz, G.J., Collins, R., Sekeres, M.A., Stone, R.M., Attar, E.C., Tosolini, A., Xu, Q., Amatangelo, M., Gupta, I., Knight, R.D., de Botton, S., Tallman, M.S., Kantarjian, H.M.

Volltext

PS1337 IVOSIDENIB (AG‐120) INDUCES DURABLE REMISSIONS AND TRANSFUSION INDEPENDENCE IN PATIENTS WITH IDH1‐MUTANT RELAPSED/REFRACTORY MYELODYSPLASTIC SYNDROME IN A PHASE 1 DOSE ESCAL... von Foran, J.M., DiNardo, C.D., Watts, J.M., Stein, E.M., Botton, S., Fathi, A.T., Prince, G.T., Stein, A.S., Stone, R.M., Patel, P.A., Tallman, M.S., Choe, S., Wang, H., Zhang, V., Dai, D., Fan, B., Yen, K.E., Kapsalis, S.M., Hickman, D., Agresta, S.V., Liu, H., Wu, B., Attar, E.C., Kantarjian, H.M.

Volltext

PS1023 MUTANT IDH1 INHIBITOR IVOSIDENIB (AG‐120) IN COMBINATION WITH AZACITIDINE FOR NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA von DiNardo, C.D., Stein, A.S., Stein, E.M., Fathi, A.T., Frankfurt, O., Schuh, A.C., Döhner, H., Martinelli, G., Patel, P.A., Raffoux, E., Tan, P., Zeidan, A., Botton, S., Kantarjian, H.M., Stone, R.M., Lam, D., Wang, X., Gong, J., Kapsalis, S.M., Hickman, D., Zhang, V., Winkler, T., Wu, B., Vyas, P.

Volltext

PS1025 IVOSIDENIB (AG‐120) INDUCES DURABLE REMISSIONS AND TRANSFUSION INDEPENDENCE IN PATIENTS WITH IDH1‐MUTANT NEWLY‐DIAGNOSED AML: UPDATED RESULTS FROM A PHASE 1 DOSE ESCALATION... von Roboz, G.J., DiNardo, C.D., Stein, E.M., Botton, S., Mims, A.S., Prince, G.T., Altman, J.K., Arellano, M.L., Donnellan, W., Erba, H.P., Mannis, G.N., Pollyea, D.A., Stein, A.S., Uy, G.L., Watts, J.M., Fathi, A.T., Kantarjian, H.M., Tallman, M.S., Choe, S., Dai, D., Fan, B., Wang, H., Zhang, V., Yen, K.E., Kapsalis, S.M., Hickman, D., Liu, H., Agresta, S., Wu, B., Attar, E.C., Stone, R.M.

Volltext

Uterovaginal anastomosis for cases of cryptomenorrhea due to cervical atresia with vaginal aplasia: benefits and risks von Zayed, M.A, Khalil, R.F, Elsetohy, K.A, Hashem, A.T, AbdAllah, A.A, Fathi, A.I

Volltext

Polyoxypregnane glycosides from Caralluma retrospiciens von Halaweish, F.T, Huntimer, E, Khalil, A.T

Volltext